# IX Layer

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ix-layer

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.ixlayer.com
- Total disclosed funding: $123M
- Latest round: Series A (Feb 24, 2021)
- Investors on record: 8

## About

Founded in 2017 and based in San Francisco, IX Layer Inc. provides innovative virtual healthcare solutions for the biopharma industry, enhancing patient access to essential services through its integrated platform.IX Layer Inc. specializes in direct-to-patient healthcare solutions. Founded in 2017, the company has conducted a total of 6 deals, with its latest round being a SERIES A funding of USD 61.30 mn raised on August 24, 2021, from investors including Aban Capital and Eleven Prime. The company was founded by Pouria Sanae, who has a background in healthcare technology.ixEngage, the primary offering of IX Layer, is a comprehensive direct-to-patient platform designed specifically for the biopharma industry. It integrates healthcare services such as telehealth, lab testing, prescription fulfillment, and benefits verification to streamline the patient journey. This platform addresses issues of accessibility and communication in healthcare, with customers primarily including biopharma companies and healthcare providers, while serving patients across various demographics. IX Layer's services are primarily utilized in the United States, with plans to expand into select international markets.The revenue model of IX Layer is based on partnerships and direct service agreements with biopharma clients and healthcare providers. Clients subscribe for access to the ixEngage platform, which offers tailored services like telehealth consultations and lab testing. This structure enables operational efficiency and enhances patient access, reflecting IX Layer's value in the healthcare ecosystem.In August 2021, IX Layer Inc. raised USD 61.30 mn in SERIES A funding to deliver scalable, adaptable solutions that connect consumers, providers, and laboratories for streamlined diagnostic testing. The company aims to expand its reach further into international markets and is developing new products to enhance its platform's capabilities. Upcoming product launches and specific geographic targets for market expansion are being formulated, with the recent funding set to support these strategic initiatives.

## Funding rounds

- Series A, Feb 24, 2021, $61M — WS Investments, Pear VC, HKB Capital, FundRx, Village Global, Eleven Prime, Aban Capital
- Series A, Feb 24, 2021, $61M — General Catalyst Partners, Pear VC

## Investors

- WS Investments (https://capitalatlas.ai/funds/ws-investments) — Series A
- Pear VC (https://capitalatlas.ai/funds/pear-vc) — Series A
- HKB Capital — Series A
- FundRx (https://capitalatlas.ai/funds/fundrx) — Series A
- Village Global (https://capitalatlas.ai/funds/village-global) — Series A
- Eleven Prime — Series A
- Aban Capital — Series A
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A